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Abstract
Despite antiretroviral therapy (ART), people living with HIV (PLWH) have higher rates of non-AIDS disorders, such as
neurocognitive (NC) impairment (NCI) than the general population. (1-3)-β-D-Glucan (BDG) is a fungal cell wall component
which serves as a biomarker for gut barrier integrity failure and microbial and fungal translocation. The primary objective of this
studywas to determine whether higher plasma and cerebrospinal fluid (CSF) levels of BDG and suPARwere associatedwith NCI
in PLWH. Paired blood and CSF samples were collected cross-sectionally from 61 male adult PLWH on ART (95% virally
suppressed) who underwent a detailed NC assessment as part of the prospective CHARTER study between 2005 and 2015. BDG
and soluble urokinase plasminogen activator receptor (suPAR) were measured in frozen blood and CSF samples while soluble
CD14 (sCD14), intestinal fatty acid binding protein (IFABP), and CD4/CD8 ratio were measured in blood only. Spearman’s rho
correlation analysis assessed associations between BDG, other biomarkers, and NC performance. Median BDG levels were
18 pg/mL in plasma (range 2–60 pg/mL) and 20 pg/mL in CSF (range 0–830 pg/mL). Higher levels of plasma BDG were
associated with worse NC performance (Spearman’s rho = − 0.32; p = 0.013) and with the presence of NCI (p = 0.027). A plasma
BDG cutoff of > 30 pg/mL was 30% sensitive and 100% specific for NCI. After adjusting for age, higher plasma suPAR levels
were also associated with worse NC performance (p < 0.01). No significant associations were observed between the remaining
biomarkers and the NC variables. Plasma levels of BDG and age-adjusted suPAR may be new biomarkers for the detection of
NCI in PLWH on suppressive ART.
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Introduction
Although antiretroviral therapy (ART) has improved sur-
vival and morbidity, people living with HIV (PLWH) have
higher rates of non-AIDS disorders, such as neurocognitive
(NC) impairment (NCI), than the general population
(Palella Jr et al. 2006; Hunt 2012; Heaton et al. 2010).
While the occurrence of severe forms of HIV-associated
dementia has decreased with ART, milder forms of NC
disorders are still estimated to affect one-third to one-half
of PLWH (Heaton et al. 2010). NCI has been associated
with chronic immune dysfunction, which persists in some
individuals despite long-term suppressive ART (Deeks
et al. 2012). While the exact mechanism is incompletely
understood and likely multifactorial, translocation of mi-
crobial and fungal products from the gastrointestinal tract
into the systemic circulation is an important driver of
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immune dysfunction and persistent inflammation during
suppressive ART (Morris et al. 2012; Ancuta et al. 2008).
Microbial and fungal translocation may therefore play a
role in the pathogenesis of NCI during HIV infection
(Morris et al. 2012; Ancuta et al. 2008), and previous stud-
ies reported associations between higher biomarkers of mi-
crobial translocations (e.g., sCD14, LPS) and worse NC
performance (Ancuta et al. 2008; Kamat et al. 2012).
(1-3)-β-D-Glucan (BDG) is a cell wall component of
most fungal species and is also a common component of
food products (Heldt et al. 2018; Prattes et al. 2014).
Among PLWH and without invasive fungal infection,
higher levels of BDG in serum are associated with gut bar-
rier integrity failure and luminal content translocation, in-
cluding microbes and/or endogenous fungal flora from the
gastrointestinal tract into the systemic circulation, and con-
sequently with HIV-associated immunosuppression and in-
flammation (Ancuta et al. 2008; Hoenigl et al. 2016a;
Farhour et al. 2018; Mehraj et al. 2019). In line with this
theory, our study team reported that BDG exhibited a strong
negat ive corre la t ion wi th the propor t ion of gut
Lactobacillales in the distal gut microbiome (low propor-
tion of gut Lactobacillales is an indicator of microbial
translocation), and positive correlation with sCD14, the
soluble form of the receptor for lipopolysaccharide (LPS)
(Hoenigl et al. 2016a). BDG levels in blood and cerebro-
spinal fluid (CSF) may have significant prognostic poten-
tial, predicting mortality in patients with various underlying
diseases (Reischies et al. 2016). In fact, previous studies
found that blood BDG levels correlated with cardiovascular
non-AIDS comorbidities among individuals with chronic
HIV infection (Ancuta et al. 2008; Hoenigl et al. 2018). In
a previous pilot study, BDG levels also correlated with
neurocognitive performance among 14 PLWH (Hoenigl
et al. 2016b).
The soluble urokinase plasminogen activator receptor
(suPAR) is another biomarker that has been correlated with
inflammation, non-AIDS events, and AIDS-related mortality
(Hoenigl et al. 2018; Lawn et al. 2007; Rasmussen et al. 2016;
Oliveira et al. 2012). The urokinase-type plasminogen activa-
tor system consists of a proteinase (uPA), a receptor (uPAR),
and inhibitors. suPAR is the soluble form of uPAR and posi-
tively correlates with the activation level of the immune sys-
tem (Hodges et al. 2015; Raggam et al. 2014; Hoenigl et al.
2013). In blood, suPAR is a marker of monocyte activation
and chronic inflammation (Hoenigl et al. 2018; Lawn et al.
2007; Rasmussen et al. 2016; Oliveira et al. 2012).
Interestingly, CSF suPAR levels are higher in PLWH with
AIDS dementia complex than in neurologically asymptomatic
adults (Cinque et al. 2004; Sidenius et al. 2004).
The primary objective of this study was to determine
whether higher plasma and CSF levels of BDG and suPAR
were associated with NCI in PLWH on ART.
Methods
In this cross-sectional analysis, we included paired plasma and
CSF samples from a cohort of 61 PLWH on ART (50% NCI
and 50% no NCI) who underwent a NC assessment as part of
the multi-site prospective CNS HIV Antiretroviral Therapy
Effects Research (CHARTER) study between 2005 and
2015 coordinated by University of California San Diego
(UCSD). The CHARTER study was funded in 2002 to ex-
plore the changing presentation of HIV neurological compli-
cations in the context of ART (Heaton et al. 2010). The UCSD
Human Research Protections Program approved the study
protocol, consent, and all study-related procedures. All study
participants provided voluntary, written informed consent be-
fore any study procedures were undertaken.
Neurocognitive assessment and comorbid conditions
The degree of NCI at the time of sample collection was mea-
sured using an established and sensitive method to determine
neurocognitive functioning among PLWH (Gonzalez et al.
2003; Carey et al. 2004; Blackstone et al. 2012). Briefly, in-
dividuals completed a comprehensive neuropsychological test
battery consistent with Frascati recommendations for
NeuroAIDS research (Carey et al. 2004). Raw NC test scores
were converted to demographically adjusted Tscores and used
to derive a global Tscore (higher scores = better performance).
Individual T scores were also converted to deficit scores and
averaged to derive a global deficit score (GDS) which was
used to classify NCI (i.e., GDS ≥ 0.5). The GDS has been
shown to detect mild, HIV-associated cognitive impairment
based on the assessment of multiple cognitive domains
(Carey et al. 2004). NCI in PLWH may not only be caused
by HIV infection but also by comorbidities. Comorbidities in
CHARTER participants were therefore classified with respect
to whether they should be considered incidental, contributing,
or confounding as causes of NCI, as described before (Heaton
et al. 2010; Antinori et al. 2007).
Testing of BDG and suPAR and other biomarkers
As part of the CHARTER study, blood samples were prospec-
tively tested for HIV RNA, CD4, and CD8 T cell counts. A
subset of 31 CSF samples was also tested for uPAR levels
(using the Quantikine Human uPAR ELISA, R&D Systems,
Minneapolis, USA; assay marked for research use only). All
samples analyzed as part of this study had been stored at −
80 °C within 90 min of collection.
Sixty-one paired plasma and CSF samples were retrospec-
tively evaluated for BDG levels using the Fungitell® assay at
the Associates of Cape Cod, Inc., research laboratories
(Associates of Cape Cod, Inc., East Falmouth, USA) and for
suPAR levels using suPARnostic assay (ViroGates,
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Copenhagen, Denmark), a CE-marked in vitro diagnostic ac-
cording to the manufacturer’s instructions. Blood plasma sam-
ples were tested for soluble cluster of differentiation 14
(sCD14) levels (a marker of monocyte activation) using an
enzyme-linked immunosorbent assay (ELISA; R&D
Systems Inc., Minneapolis, MN, USA), and intestinal fatty
acid binding protein (IFABP, marker of gut epithelial dysfunc-
tion; R&D Systems Inc., Minneapolis, MN, USA) according
to the manufacturer’s instructions.
Statistical analysis
For statistical analysis, SPSS 25 (SPSS Inc., Chicago, IL,
USA) was used. BDG, suPAR, and other biomarkers as well
as global T scores were used primarily as continuous vari-
ables. GDS was used as a binary (cutoff ≥ 0.5, which defines
NCI), or continuous variable. When using GDS as a binary
variable, biomarkers and biomarker combinations were eval-
uated using theWilcoxon rank-sum test and receiver operating
characteristic (ROC) curve analysis for the determination of
area under the curve (AUC) values. Correlations between
levels of BDG, other biomarkers, global T scores, and GDS
were calculated using Spearman rho correlation analysis due
to the non-normal distributions of GDS scores and other bio-
markers. We further calculated the coefficient of variability
between the suPAR and the uPAR assays. Power calculation
revealed that a sample size of 61 plasma and CSF samples
provides at least 80% power (alpha = 0.05) to detect an effect
size 0.73 when comparing BDG or suPAR between those with
NCI versus others. Univariate and multivariable binary logis-
tic regression analyses assessed the predictors of NCI.
Variables with a p value < 0.2 in univariate analysis were
included in the multivariable model. Variables in the final
model were selected with a stepwise forward procedure.
Model discrimination was assessed by the goodness-of-fit
Hosmer-Lemeshow statistics. Odds ratios (ORs) and adjusted
odds ratios (aOR) including 95% confidence intervals (CIs)
were calculated, and a p value of < 0.05 was considered sta-
tistically significant.
Results
The study cohort was comprised of 61 male and mostly white
PLWH, with a median age of 48 years (range 27–63 years),
that were without symptoms of opportunistic infections.
Overall, 58/61 (95%) of participants had undetectable HIV
RNA in blood plasma, and 59/61 (97%) had undetectable
HIV RNA in CSF at the time of sampling. Median CD4+ T
cell count was 589 cells/μL (IQR 407–776, range 69–
1587 cells/μL), median CD4+/CD8+ T cell ratio was 0.72
(IQR 0.44–1.01, range 0.11–2.00). Clinical characteristics
are summarized in Table 1.
Median BDG level was 18 pg/mL in plasma (range 2–
60 pg/mL) and 20 pg/mL in CSF (range 0–830 pg/mL).
Higher levels of plasma BDG were associated with lower
global T scores (Spearman’s rho = − 0.32; p = 0.013), and
more severe cognitive impairment as measured by the GDS
(Spearman r = 0.35; p = 0.006; Fig. 1). No other significant
associations were observed between the remaining bio-
markers and the NC variables: CSF BDG and GDS (r =
0.23), plasma suPAR and GDS (r = 0.19), CSF suPAR and
Table 1 Demographics and clinical metrics of study participants
Characteristics Total subjects
(N = 61)
Male sex, n (%) 61 (100)
Race, n (%)
White 32 (52)
Black 20 (33)
Hispanics 9 (15)
Age, years, median (range) 48 (27–62)
Undetectable HIV RNA plasma, n (%) 58 (95)
Undetectable HIV RNA CSF, n (%) 59 (97)
CD4/CD8 ratio, median (range) 0.72 (range
0.11–2.00).
CD4+ cell count1, cells/μL, median (range) 589 (69–1587)
Nadir CD4+ cell count1, cells/μL, median
(range)
212 (3–816)
Neurocognitive impairment (GDS > 0.5), n (%) 33 (54)
Smoking status, n (%) 48 (79)
Duration on current ART, years, median (range) 2 (0–9)
Duration on any ART, years, median (range) 5 (0–19)
ART regimens*
NNRTI-based, n (%) 23 (43)
PI-based, n (%) 25 (46)
Other regimens, n (%) 6 (11)
CSF, cerebrospinal fluid; *ART regiments available for 54 study partici-
pants; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, prote-
ase inhibitors
Fig. 1 Scatterplots of correlation of plasma beta-D-glucan levels with
global deficit scores
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GDS (r = − 0.022), sCD14 and GDS (r = − 0.033), iFABP and
GDS (r = 0.057), and CD4/CD8 ratio and GDS (r = − 0.028).
Interestingly, when plasma suPAR levels were adjusted for
age, they were significantly associated with lower global T
scores (beta − 0.317; p = 0.014) and with higher GDS (beta
0.342; p = 0.008).
Comorbidities were classified as incidental in 32 partici-
pants, contributing to 19 participants, and confounding as
causes of NCI in 10 participants. Correlation between plasma
and CSF biomarkers and measures of NCI did not change
after exclusion of participants with confounding comorbidities
(plasma BDG level and global T scores r = − 0.33; plasma
BDG and GDS r = 0.31, other correlations not shown).
Individuals with NCI (i.e., GDS ≥ 0.5, n = 33) had higher
plasma BDG levels compared to unimpaired individuals (me-
dian 21 pg/mL, range 5–60 versus median 16 pg/mL, range 2–
30; p = 0.027; AUC = 0.666, 95%CI 0.530–0.801), and there
was also a trend towards higher CSF BDG levels in impaired
individuals (p = 0.083; AUC = 0.631, 95%CI 0.486–0.776;
Fig. 2). Plasma BDG levels > 30 pg/mL were observed in
30% of participants with NCI but not a single participant
without NCI. No significant difference was observed for other
biomarkers, including suPAR, sCD14, and IFABP.
In the univariate and multivariate model, only plasma
BDG levels remained a predictor of NCI, while all other
biomarkers and variables evaluated did not (Table 2; not
displayed plasma IFABP, and plasma sCD14, both p > 0.8
in univariate analysis).
Plasma levels of BDG correlated significantly with plasma
suPAR levels (rho = 0.31, p = 0.016), but not with other
biomarkers.
CSF suPAR levels determined as part of this study corre-
lated significantly with CSF uPAR levels determined at the
time of sample collection as part of the CHARTER study with
an assay marked for research use only (Spearman rho = 0.795;
p < 0.001; n = 31). The coefficient of variation between the
two assays (log10 values used for the research only assay)
was mean 0.76, SD 0.23.
Discussion
Microbial imbalances in the gut likely play an important role
in the pathogenesis of NCI (Dinan et al. 2015; Perez-Santiago
et al. 2013; Petra et al. 2015). Translocation of bacterial and
fungal products is one of many drivers of systemic inflamma-
tion and might contribute to HIV disease progression
(Ramendra et al. 2019; Lozupone et al. 2013), as well as to
NCI (Ancuta et al. 2008; McLaurin et al. 2019; Hoenigl
2019). As part of this study, we measured novel biomarkers
of microbial translocation and immune activation in blood and
CSF in a cohort of 61 PLWH on ART who underwent a de-
tailed battery of NC assessments. We also compared
Fig. 2 Plasma and CSF beta-D-glucan levels in those with neurocognitive
impairment (i.e., global deficit scores > 0.5) versus those without
neurocognitive impairment
Table 2 Univariate and
multivariable binary logistic
regression models for predicting
neurocognitive impairment
Variables for predicting
neurocognitive impairment
(n = 61)
OR 95% CI p value aOR 95% CI p value
Univariate Model Multivariable Model
Plasma BDG (per pg/mL) 1.066 1.010–1.124 0.020 1.066 1.010–1.124 0.020
CSF BDG (per pg/mL) 1.003 0.966–1.010 0.383
Plasma suPAR 1.165 0.862–1.574 0.321
Current CD4 0.999 0.997–1.001 0.290
Current CD4/CD8 ratio 1.587 0.402–6.262 0.509
Nadir CD4 count 0.997 0.994–1.000 0.083 – – n.s.
Months of ART exposure 1.004 0.995–1.013 0.341
Age (per year) 1.041 0.977–1.110 0.213
Higher education category 1.046 0.865–1.264 0.644
Current smoker 0.627 0.195–2.019 0.434
*Chi square 6.731; p = 0.566 Hosmer Lemeshow; Forward Wald binary logistic regression
OR, odds ratio; aOR, adjusted odds ratio; CSF, cerebrospinal fluid; n.s., not significant
J. Neurovirol.
performance for these novel biomarkers with established
markers of monocyte activation (sCD14), immune dysfunc-
tion (CD4/CD8 ratio), and gut leakage (IFAB).
We found that in our cohort of chronically infected PLWH
on suppressive ART, median levels of BDG in blood plasma
(18 pg/mL) were similar to a previous study with a similar
cohort of PLWH where the level of BDG was 15 pg/mL
(Hoenigl et al. 2016b). Higher BDG levels (median 66 pg/
mL) were reported from another study where PLWH began
ART very early during infection and also had shorter follow-
up times (Hoenigl et al. 2016a). Overall, the levels in our
cohort were within the range of BDG levels previously report-
ed for healthy subjects (Odabasi et al. 2004; Pruller et al.
2014), indicating that blood BDG levels may not consistently
differentiate between those with and without HIV infection.
Nevertheless, an increasing number of studies support BDG
as a biomarker for microbial translocation and immune acti-
vation among those with HIV infection (Ancuta et al. 2008;
Hoenigl et al. 2016a, b, 2018; Farhour et al. 2018; Mehraj
et al. 2019; Hoenigl 2019). By contrast, the levels of BDG
in CSF in our cohort were higher as compared to the cohort
that received early ART (20 pg/mL compared to 5 pg/mL)
(Hoenigl et al. 2016a). Subsequently, we found that elevated
levels of BDG in blood plasma (but not in CSF) were signif-
icantly associated with worse NC performance in chronically
infected PLWH on suppressive ART. This is in line with a
previous smaller study from our group, showing a similar
association in a group of 14 PLWH who started ART during
early HIV infection (Hoenigl et al. 2016b). Also, higher plas-
ma suPAR levels were significantly associated with worse NC
performance, but only after adjusting for age. Interestingly, in
our cohort, none of the other measured biomarkers (i.e.,
sCD14, IFABP, and CD4/CD8 ratio) were associated with
NCI, which is in contrast to other studies (Lyons et al.
2011). These discrepancies might be because of differences
in study populations, stage of HIV disease, and treatment sta-
tus. Other limitations in our current study include the limited
sample size and the cross-sectional design which may have
biased our analysis and limited our ability to detect associa-
tions between NC performance and some of our other mea-
sured biomarkers.
Despite the mentioned limitations, our study confirms pre-
vious findings that elevated plasma levels of BDG may be an
indicator of gut barrier integrity failure and an independent
biomarker associated with NC performance in PLWH on sup-
pressive ART. The samemay be true for plasma suPAR levels,
once adjusted for age.
Identification of biomarkers (or combination of bio-
markers) that are sensitive to HIV-associated NC performance
is essential to avenues of future research. While our findings
might have clinical implications, future research is needed to
validate our findings in an independent cohort. Incorporation
of independent measurements of HIV-associated brain
dysfunction (e.g., neuroimaging or neuropathological data)
may provide further support of associations between BDG,
suPAR, and NC performance. Future research is also needed
to determine associations between biomarkers and the profile
and pattern of neurocognitive performance, which is not fea-
sible using dichotomous impairment outcome variables.
Finally, longitudinal studies are needed to determine the prog-
nostic and clinical utility of biomarkers such as BDG and
suPAR in identifying those who may be at risk for subsequent
neurocognitive decline.
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